HC Wainwright Reiterates Buy Rating for Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. (NASDAQ:VKTX)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Friday. They currently have a $7.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 155.47% from the company’s previous close.
VKTX has been the subject of several other research reports. Maxim Group reiterated a “buy” rating and issued a $5.00 price objective on shares of Viking Therapeutics in a research report on Monday, September 11th. ValuEngine downgraded Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th.
Viking Therapeutics (VKTX) opened at $2.74 on Friday. Viking Therapeutics has a 52-week low of $0.88 and a 52-week high of $3.24.
Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.03). equities analysts predict that Viking Therapeutics will post -0.81 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Sabby Management LLC bought a new position in Viking Therapeutics in the 2nd quarter valued at $525,000. Sphera Funds Management LTD. bought a new position in Viking Therapeutics in the 3rd quarter valued at $554,000. Renaissance Technologies LLC raised its position in Viking Therapeutics by 62.9% in the 1st quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock valued at $388,000 after purchasing an additional 102,600 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in Viking Therapeutics in the 2nd quarter valued at $124,000. Finally, Citadel Advisors LLC bought a new position in Viking Therapeutics in the 3rd quarter valued at $108,000. Hedge funds and other institutional investors own 5.54% of the company’s stock.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.